Infectious complications after 2-chlorodeoxyadenosine therapy

European Journal of Haematology

Volumn 56, Issue 4, 1996, Pages 235-240

  Van Den Neste, E ^a   Delannoy, A ^a,b   Vandercam, B ^a   Bosly, A ^a   Ferrant, A ^a   Mineur, P ^a   Montfort, L ^a   Martiat, P ^a   Straetmans, N ^a   Filleul, B ^a   Michaux, J L ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Hospital de Jolimont   (Belgium)

Author keywords

7 Chlorodeoxyadenosine; Chronic lymphocytic leukemia; Hairy cell leukemia; Infection; Non Hodgkin's lymphoma; Waldenstrom's macroglobulinemia

Indexed keywords

CLADRIBINE;

ADULT; AGED; ARTICLE; FEMALE; HERPES VIRUS INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 9344231435     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb01935.x     Document Type: Article

References (27)

1. PIRO LD, CARRERA CJ, CARSON DA, BEUTLER E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990: 332: 1117-1121.
2. PIRO LD, CARRERA CJ, BEUTLER E, CARSON DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988: 72: 1069-1073.
3. DIMOPOULOS MA, KANTARJIAN H, ESTEY E, et al. Treatment of Waldenström's macroglobulinemia with 2-CdA. Ann Intern Med 1993: 118: 195-198.
4. HOFFMAN M, TALLMAN MS, HAKIMIAN D, et al. 2-CdA is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 1994: 12: 788-792.
5. KAY AC, SAVEN A, CARRERA CJ, et al. 2-CdA treatment of low-grade lymphomas. J Clin Oncol 1992: 10: 371-377.
6. SAVEN A, FIGUEROSA ML, PIRO LD, ROSENBLATT JD. 2-CdA to treat refractory histiocytosis X. N Engl J Med 1993: 329: 734-735.
7. SIPE JC, ROMINE JS, KOZIOL JA, MCMILLAN R, ZYROFF J, BEUTLER E. Cladribine in the treatment of chronic progressive multiple sclerosis. Lancet 1994: 344: 9-13.
8. SAVEN A, PIRO LD, LEMON RH, et al. Complete hematologic remission in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-CdA. Cancer 1994: 73: 2953-2963.
9. SEYMOUR JF, KURZOCK R, FREIREICH EJ, ESTEY EH. 2-CdA induces durable remissions and prolonged suppression of CD4 lymphocyte count in patients with hairy cell leukemia. Blood 1994: 83: 2906-2911.
10. JULIUSSON G, LENKEI R, LILIEMARK J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocytes subsets after treatment with 2-CdA. Blood 1994: 83: 3679-3681.
11. NCI COMMON TOXICITY CRITERIA. National Cancer Institute, Division of Cancer Treatment, 1988.
12. CHESON BD, BENNETT JM, RAI KR, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Recommendations of the NCI-sponsored working group. Am J Hematol 1988: 29: 152-163.
13. DELANNOY A, FERRANT A, MARTIAT P, BOSLY A, MICHAUX JL. 2-chlorodeoxyadenosine and multiple myeloma. Eur J Haematol 1994: 53: 181-182.
14. BETTICHER DC, FEY MF, VON ROHR A, et al. High incidence of infection after 2-CdA therapy in patients with malignant lymphomas and chronic and acute leukemias. Ann Oncol 1994: 5: 57-64.
15. DIMOPOULOS MA, KANTARJIAN H, WEBER D, et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994: 12: 2694-2698.
16. O'BRIEN S, KURZROCK R, DUVIC M, et al. 2-chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994: 84: 733-738.
17. SANTANA VM, MIRRO J, HARWOOD FC, et al. A phase I clinical trial of 2-CdA in pediatric P. with acute leukemia. J Clin Oncol 1991: 9: 416-422.
18. SANTANA VM, HURWITZ CA, BLAKLEY RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994: 84: 1237-1242.
19. SAVEN A, KAWAZAKI H, CARRERAS CJ, et al. 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J Clin Oncol 1993: 11: 671-678.
20. SAVEN A, CARRERA CJ, CARSON DA, BEUTLER E, PIRO LD. 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 1991: Suppl: 133-138.
21. O'BRIEN S, KANORZIAN H, ESTEY E, et al. Lack of effect of 2-CdA therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994: 330: 319-322.
22. ESTEY EH, KURZROCK R, KANTARJIAN HM, et al. Treatment of hairy cell leukemia with 2-CdA. Blood 1992: 79: 882-887.
23. LAURIA F, RONDELLI D, RASPADORI D, BENFENATI D, TURA S. Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy cell leukemia. Eur J Haematol 1994: 52: 16-20.
24. TALLMAN MS, HAKIMIAN D, VARIAKOJIS D, et al. A single cycle of 2-CdA results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992: 80: 2203-2209.
25. JULIUSSON G, LENKEI R, TJONNFORD G, HELDAL D, LILIEMARK J. Low-dose cladribine for symptomatic hairy cell leukemia. Br J Haematol 1995: 89: 637-689.
26. JULIUSSON G, LILIEMARK J. High complete remission rate from 2-CdA in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993: 11: 679-689.
27. 2 S.C. Day 1-7) normalizes cytopenia in hairy cell leukemia (HCL) as quick as standard dose with less lymphopenia - no improvement by GM-CSF. Blood 1994: Suppl 1: 462a.